ReviewDrug metabolism and disposition: the biological fate of chemicals2018
How to Determine the Role of the Microbiome in Drug Disposition.
Review in Drug metabolism and disposition: the biological fate of chemicals, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Modulating drug response through the gut microbiome: pathways to precision therapy.Archives of microbiology · 2026Review
- Microbiota-based PBPK model: new approach methodology for assessing the kinetics of drugs and chemicals.Frontiers in pharmacology · 2026Review
- Dopamine and the Gut Microbiota: Interactions Within the Microbiota-Gut-Brain Axis and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
- Emerging advances in intestinal models for in vitro preclinical research.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025Review
- Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response.Annual review of pharmacology and toxicology · 2025Review
- Application of In Vitro Digestion Models in the Evaluation of Dietary Supplements.Foods (Basel, Switzerland) · 2024Review
- Human gut Actinobacteria boost drug absorption by secreting P-glycoprotein ATPase inhibitors.iScience · 2024Article
- Bioaccumulation and biotransformation of simvastatin in probiotic bacteria: A step towards better understanding of drug-bile acids-microbiome interactions.Frontiers in pharmacology · 2023Article
- Exploring the role of gut microbiota in advancing personalized medicine.Frontiers in microbiology · 2023Review
- Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.Nature microbiology · 2022Article
- The influence of the gut microbiota on the bioavailability of oral drugs.Acta pharmaceutica Sinica. B · 2021Review
- Fundamental dietary specialisation explains differential use of resources within a koala population.Oecologia · 2021Article
- The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation.Pharmaceutics · 2021Article
- The Microbiome and the Gut-Liver-Brain Axis for Central Nervous System Clinical Pharmacology: Challenges in Specifying and Integrating In Vitro and In Silico Models.Clinical pharmacology and therapeutics · 2020Review
- Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.Nature reviews. Rheumatology · 2020Review
- AnToxicology reports · 2020Article
- Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
With a paradigm shift occurring in health care toward personalized and precision medicine, understanding the numerous environmental factors that impact drug disposition is of paramount importance. The highly diverse and variant nature of the human microbiome is now recognized as a factor driving interindividual variation in therapeutic outcomes. The purpose of this review is to provide a practical guide on methodology that can be applied to study the effects of microbes on the absorption, distribution, metabolism, and excretion of drugs. We also highlight recent examples of how these methods have been successfully applied to help build the basis for researching the intersection of the microbiome and pharmacology. Although in vitro and in vivo preclinical models are highlighted, these methods are also relevant in late-phase drug development or even as a part of routine after-market surveillance. These approaches will aid in filling major knowledge gaps for both current and upcoming therapeutics with the long-term goal of achieving a new type of knowledge-based medicine that integrates data on the host and the microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.